Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
Colhoun, Helen M, Robinson, Jennifer G, Farnier, Michel, Cariou, Bertrand, Blom, Dirk, Kereiakes, Dean J, Lorenzato, Christelle, Pordy, Robert, Chaudhari, UmeshVolume:
14
Année:
2014
Langue:
english
Journal:
BMC Cardiovascular Disorders
DOI:
10.1186/1471-2261-14-121
Fichier:
PDF, 416 KB
english, 2014